To simulate this multiplexed perturbant condition and test the ability of the different targeted drugs to attenuate abnormal signaling from multiplexed agonists, patient breast cancer cells were stimulated with a growth factor cocktail of EGF, NRG1b, and HGF (N/E/H) to simultaneously initiate signaling via the HER-family and c-Met receptors. This evidence concerns the gene EGF and breast cancer.